What question did this study set out to answer?

To evaluate whether adding blinatumomab to combination chemotherapy improves disease-free survival in pediatric patients with newly diagnosed standard-risk B-cell acute lymphoblastic leukemia at average or higher risk of relapse.

December 7, 2024New England Journal of MedicineOpen Access

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

View Full Paper

Ask AI

Bookmark

Authors

SGSumit GuptaNorth Carolina Agricultural and Technical State University RRRachel E. RauSeattle Children's Hospital JKJohn A. KairallaUniversity of Florida Health

Discussion

Member takes

Implication

Randomized trial demonstrates improved disease-free survival with added blinatumomab in pediatric standard-risk B-cell leukemia, highlighting a superior frontline therapy.

Key Points

To evaluate whether adding blinatumomab to combination chemotherapy improves disease-free survival in pediatric patients with newly diagnosed standard-risk B-cell acute lymphoblastic leukemia at average or higher risk of relapse.
Randomized clinical trial (AALL1731, ClinicalTrials.gov number NCT03914625) involving pediatric patients with newly diagnosed standard-risk B-cell acute lymphoblastic leukemia.
Evaluated the therapeutic addition of blinatumomab to standard combination chemotherapy regimens in patients stratified to average or higher risk of relapse.
The addition of blinatumomab to combination chemotherapy significantly improved disease-free survival among pediatric standard-risk B-cell acute lymphoblastic leukemia patients at average or higher risk of relapse.
Specific hazard ratios, confidence intervals, and per-arm survival rates were not reported in the available trial abstract.

Cite This Study

Gupta et al. (2024) studied this question.

synapsesocial.com/papers/69d953dcf20ef2633068486c https://doi.org/10.1056/nejmoa2411680

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates improved disease-free survival with added blinatumomab in pediatric standard-risk B-cell leukemia, highlighting a superior frontline therapy.

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

Discussion

Member takes

Implication

Key Points

Cite This Study

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider